Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

VANCOUVER, BC-Drug dependence is not physical dependence alone, nor is it the same as drug tolerance. "Drug dependence is primarily psychological dependence, or compulsive use of drugs for their mood-altering effects and continued use despite harm," David E. Joranson, MSSW, said at the WHO workshop on cancer pain.

VANCOUVER, BC-Drug dependence is not physical dependence alone,nor is it the same as drug tolerance. "Drug dependence isprimarily psychological dependence, or compulsive use of drugsfor their mood-altering effects and continued use despite harm,"David E. Joranson, MSSW, said at the WHO workshop on cancer pain.

The WHO Expert Committee on Drug Dependence recently clarifiedthat a cancer patient who has been receiving opioids for painand who stops the drug would go through a withdrawal syndromeas evidence of physical dependence, but that individual is notconsidered to be drug dependent.

"Physical dependence by itself is no longer sufficient todefine drug dependence or addiction," Mr. Joranson said."It is important for us to teach this and to clear up themythology about the relationship between opioid analgesia andaddiction."

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content